Igaue Shota, Okuno Takayuki, Ishibashi Hajime, Nemoto Masaru, Hiyoshi Masaya, Kawasaki Hiroshi, Saitoh Hitoaki, Saitoh Makoto, Akagi Kiwamu, Yamamoto Junji
Department of Gastrointestinal Surgery, Ibaraki Cancer Center, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309-1793, Japan.
Department of Gastroenterology, Ibaraki Cancer Center, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309-1793, Japan.
Oncol Lett. 2022 May 17;24(1):211. doi: 10.3892/ol.2022.13332. eCollection 2022 Jul.
The standard treatment for colorectal cancer has always been surgery and chemotherapy, which may be used in combination to treat patients. Immune checkpoint inhibitors have been a significant advancement in the standard treatment of metastatic, unresectable colorectal cancer with deficient mismatch repair. However, little information is available about their use in neoadjuvant and conversion settings with only a few case reports and only one phase 2 trial. The present study reports the case of a large, locally advanced right-sided metastatic deficient mismatch repair/microsatellite instability-high colon cancer, which showed a pathological complete response after combination treatment with nivolumab and ipilimumab. To the best of our knowledge, resected metastatic colon cancer with a pathological complete response after treatment using dual immune checkpoint inhibitors has not been previously reported. Overall, this case report suggests the use of immune checkpoint inhibitors before colorectal surgery.
结直肠癌的标准治疗方法一直是手术和化疗，这两种方法可联合用于治疗患者。免疫检查点抑制剂是治疗错配修复缺陷的转移性、不可切除结直肠癌标准治疗中的一项重大进展。然而，关于它们在新辅助治疗和转化治疗中的应用信息很少，仅有几例病例报告和一项2期试验。本研究报告了一例大型局部晚期右侧转移性错配修复缺陷/微卫星高度不稳定结肠癌病例，该病例在接受纳武单抗和伊匹单抗联合治疗后出现了病理完全缓解。据我们所知，此前尚未报道过使用双重免疫检查点抑制剂治疗后出现病理完全缓解的转移性结肠癌切除病例。总体而言，本病例报告提示了在结直肠癌手术前使用免疫检查点抑制剂的可能性。
